NVSNovartis PharmaceuticalsRunning, no new patients
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Advanced Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 24 (final count)
- Started
- Jan 8, 2021
- Main results expected
- Feb 26, 2027
- Fully finished
- Feb 27, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
[Part 1] The incidence of Dose Limiting Toxicities (DLTs) of alpelisib in combination with fulvestrant
Measured over: From Cycle 1 Day 1 to Cycle 2 Day 28 (Cycle = 28 days)
[Part 2] Overall Response Rate (ORR) in CDK4/6 inhibitor naive participants
Measured over: Up to approximately 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04524000 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC